Evidence map›Paper›PMID 38158172›Full record

ArticleCryobiology2024

CPA toxicity screening of cryoprotective solutions in rat hearts.

Casey J Kraft, Bat-Erdene Namsrai, Diane Tobolt, Michael L Etheridge, Erik B Finger, John C Bischof

Open access · greenAbstract read
In one paragraph

Article in Cryobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Casey J KraftDepartment of Biomedical Engineering, University of Minnesota, USA.
Bat-Erdene NamsraiDepartment of Surgery, University of Minnesota, USA.
Diane ToboltDepartment of Surgery, University of Minnesota, USA.
Michael L EtheridgeDepartment of Mechanical Engineering, University of Minnesota, USA.
Erik B FingerDepartment of Surgery, University of Minnesota, USA. Electronic address: efinger@umn.edu.
John C BischofDepartment of Biomedical Engineering, University of Minnesota, USA; Department of Mechanical Engineering, University of Minnesota, USA; Institute for Engineering in Medicine, University of Minnesota, USA. Electronic address: bischof@umn.edu.
University of Minnesota · US

Funding

Organ banking for transplant—kidney cryopreservation by vitrification and novel nanowarming technologyR01DK117425 · NIDDK · UNIVERSITY OF MINNESOTA · PI JOHN C BISCHOF, Erik Brian Finger · 2018 to 2026
$4.9M
Cryopreservation and nanowarming enables whole liver banking for transplantation, cell therapy and biomedical researchR01DK132211 · NIDDK · UNIVERSITY OF MINNESOTA · PI JOHN C BISCHOF, Erik Brian Finger · 2023 to 2026
$2.6M
Breakthrough Tissue and Organ Preservation and Transplantation Using Scaled-Up Nanowarming TechnologyR01HL135046 · NHLBI · UNIVERSITY OF MINNESOTA · PI BISCHOF, JOHN C, FINGER, ERIK BRIAN · 2017 to 2020
$2.6M
Engineering optimization and scaling enables high quality pancreatic islet cryopreservation for banking and transplantR01DK131209 · NIDDK · UNIVERSITY OF MINNESOTA · PI BISCHOF, JOHN C, FINGER, ERIK BRIAN · 2021 to 2024
$2.3M
Multidisciplinary training in cardiovascular engineeringT32HL139431 · NHLBI · UNIVERSITY OF MINNESOTA · PI BAROCAS, VICTOR H, TRANQUILLO, ROBERT T · 2019 to 2023
$1.2M
NHLBI NIH HHS R01 HL135046NHLBI NIH HHS T32 HL139431NIDDK NIH HHS R01 DK117425NIDDK NIH HHS R01 DK131209NIDDK NIH HHS R01 DK132211
6 · The paper itself

Abstract

In clinical practice, donor hearts are transported on ice prior to transplant and discarded if cold ischemia time exceeds ∼5 h. Methods to extend these preservation times are critically needed, and ideally, this storage time would extend indefinitely, enabling improved donor-to-patient matching, organ utilization, and immune tolerance induction protocols. Previously, we demonstrated successful vitrification and rewarming of whole rat hearts without ice formation by perfusion-loading a cryoprotective agent (CPA) solution prior to vitrification. However, these hearts did not recover any beating even in controls with CPA loading/unloading alone, which points to the chemical toxicity of the cryoprotective solution (VS55 in Euro-Collins carrier solution) as the likely culprit. To address this, we compared the toxicity of another established CPA cocktail (VEG) to VS55 using ex situ rat heart perfusion. The CPA exposure time was 150 min, and the normothermic assessment time was 60 min. Using Celsior as the carrier, we observed partial recovery of function (atria-only beating) for both VS55 and VEG. Upon further analysis, we found that the VEG CPA cocktail resulted in 50 % lower LDH release than VS55 (N = 4, p = 0.017), suggesting VEG has lower toxicity than VS55. Celsior was a better carrier solution than alternatives such as UW, as CPA + Celsior-treated hearts spent less time in cardiac arrest (N = 4, p = 0.029). While we showed substantial improvement in cardiac function after exposure to vitrifiable concentrations of CPA by improving both the CPA and carrier solution formulation, further improvements will be required before we achieve healthy cryopreserved organs for transplant.

Indexed as

Heart TransplantationOrgan Preservation SolutionsAnimalsCryopreservationCryoprotective AgentsIceRatsTissue DonorsCryoprotective AgentsIceOrgan Preservation SolutionsCPA toxicityCryopreservationHeartPerfusionVitrification

Identifiers

PMID38158172
PMCPMC11758884
OpenAlexW4390276980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.